Association Between Adalimumab Dosing Interval and Uveitis Recurrence in Patients with Ankylosing Spondylitis.

Biomedicines · 2025 · PMC12467712 · PMID 41007651

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally non-significantno p-value reported

In the unadjusted analysis, the adalimumab dosing interval was significantly associated with an increased OR for uveitis recurrence as dosing intervals lengthened, while BASDAI was marginally non-significant.

also in 1,493 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.